PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study
Status:
Completed
Trial end date:
2022-10-05
Target enrollment:
Participant gender:
Summary
The overall goal is to provide an innovative approach to restage patients with biochemical
recurrence of prostate cancer by using hybrid PET/MR with innovative radiotracers (68Ga-PSMA
and 68Ga-RM2)